Aortic Disruption: Artivion Just Shook the MedTech Industry With THIS Growth! скачать в хорошем качестве

Aortic Disruption: Artivion Just Shook the MedTech Industry With THIS Growth!

Artivion (NASDAQ: AORT) just delivered one of its most impressive earnings updates to date at the Canaccord 45th Annual Growth Conference. CEO Pat Mack and newly promoted CFO Lance Perry dropped major updates — and some of the numbers were shockingly bullish. Aired August 12, 2025 🔥Join my Patreon to unlock exclusive BUY signals for stocks and options! https://tinyurl.com/4uf6jpcv 🌟Limited time offer: Sign up for Moomoo and deposit just $100 get $50 cash back instantly. Plus, enjoy 60 days commission-free trading and 6% APY on idle funds. https://tinyurl.com/mshhykpn 🚀 FREE Public Discord!   / discord   ✅If you like the latest analyst ratings and data, check out (FREE) https://bit.ly/3BM3mCk FREE Seeking Alpha Premium 7 Day trial- https://www.sahg6dtr.com/Z8ZKPB/R74QP/ ⭐⭐⭐⭐⭐𝗖𝗢𝗡𝗡𝗘𝗖𝗧 𝗪𝗜𝗧𝗛 𝗠𝗘⭐⭐⭐⭐⭐ All Links | ► https://allmylinks.com/financial-journey Twitter | ► / finjourney Company Profile Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THORACIC 3G products, and NEXUS products. It also offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries and aneurysmal iliac side branches; Tuva BX, a balloon-expandable peripheral stent graft to treat arterial ruptures, aneurysms, and other peripheral vascular system pathologies; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves, and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures for mitral chordal replacement; and pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.